🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Katja Schulze

ORCID: 0000-0003-3704-5651

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study”.

Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study

Cancer Discovery(2021)10.1158/2159-8290.cd-21-0450

N/A

3.0DataRank · unranked

101 citations

John D. Hainsworth, Razelle Kurzrock, David R. Spigel, Howard A. Burris, Christopher J. Sweeney +9 more

Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors

JAMA Oncology(2022)10.1001/jamaoncol.2022.0212

N/A

1.1DataRank · unranked

40 citations

Suyu Liu, Arvind Dasari, David R. Fogelman, Priya Bhosale, Armeen Mahvash +21 more

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002891

N/A

0.854DataRank · unranked

296 citations

Ferdinandos Skoulidis, Meagan Montesion, Katja Schulze, Ilze Bāra, Vincent K. Shen +33 more

Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma

Cancer Discovery(2021)10.1158/2159-8290.cd-21-0331

N/A

0.648DataRank · unranked

74 citations

Suyu Liu, Michael J. Overman, Anneleis F. Willett, Mark Knafl, Szu-Chin Fu +29 more

Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non–small cell lung cancer

Journal of Thoracic and Cardiovascular Surgery(2022)10.1016/j.jtcvs.2022.10.007

N/A

0.568DataRank · unranked

43 citations

Alan Nicholas, G. Alexander Patterson, Salama N. Waqar, Eric M. Toloza, Eric B. Haura +24 more

Data from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma

(2023)10.1158/2159-8290.c.6549433.v1

N/A

0DataRank · unranked

0 citations

Suyu Liu, Michael J. Overman, Anneleis F. Willett, Mark Knafl, Szu‐Chin Fu +29 more

Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study

Oral Oncology(2024)10.1016/j.oraloncology.2024.106747

N/A

0DataRank · unranked

2 citations

S. Liu, Priya Bhosale, Mehmet Altan, W. Darbonne, Katja Schulze +14 more